BioTuesdays

Category - Feature

Feature

DARA’s sales team goes on a Mission

By Len Zehr A new sales and marketing venture with a unit of Mission Pharmacal gives DARA BioSciences (NASDAQ:DARA) a formidable leg up in the oncology supportive care sector to address ongoing areas of medical need. A...

November 12, 2013
Feature

In conversation with Paul Lem

By Len Zehr As CEO and co-founder of closely-held Spartan Bioscience, Dr. Paul Lem has a diverse background in clinical medicine, molecular biology research and as a biotech entrepreneur. Prior to co-founding Spartan in...

November 5, 2013
Feature

NeoStem completing enrollment in heart trial

By Len Zehr NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data...

October 29, 2013
Feature

Heat Biologics readies proof-of-concept studies

By Len Zehr After a successful $27-million IPO in the summer, Heat Biologics (NASDAQ:HTBX) plans to begin two proof-of-concept trials later this year of its platform to transform living cancer cells into pumps that...

October 22, 2013
Feature

CytRx awaiting soft tissue sarcoma data in December

By Len Zehr What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when...

October 15, 2013
Feature

Aethlon readies U.S. study of the Hemopurifier

By Len Zehr Aethlon Medical (OTCQB:AEMD), sporting FDA approval of an investigational drug exemption (IDE), plans to begin treating patients infected with hepatitis C virus (HCV) early next year in a feasibility study...

October 1, 2013
Feature

In conversation with Kelly Close

By Len Zehr As president and founder of Close Concerns, a healthcare information firm focused on diabetes and obesity, Kelly Close says her passion comes from her extensive professional work as well as her personal...

September 24, 2013
Feature

diaDexus awaiting GSK’s darapladib pivotal results

By Len Zehr Positive data from GlaxoSmithKline’s two pivotal trials of its darapladib cardiovascular drug could provide a huge boost to the utilization of diaDexus’ (OTCQB:DDXS) PLAC test, which is being used on...

September 17, 2013
Feature

In conversation with Zoe Barry

By Len Zehr As founder and CEO of ZappRx, a consumer engagement company focused on improving the electronic prescription process, Zoe Barry began her career as an analyst at hedge fund, Dawson Capital, in New York...

September 10, 2013
Feature

Stereotaxis sees Japanese reimbursement by year end

By Len Zehr After receiving regulatory clearance in Japan of its Niobe Remote Magnetic Navigation system for cardiac ablations last March, Stereotaxis (NASDAQ:STXS) now expects to achieve reimbursement approval by the...

September 3, 2013